B-cell depletion for rheumatic diseases: Where are we? CME

MedGenMed Medscape General Medicine

Volumn 7, Issue 2, 2005, Pages

  Cohen, Stanley B ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; IDIOTYPIC ANTIBODY; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MONOCLONAL ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; PREDNISONE; RHEUMATOID FACTOR; RITUXIMAB;

AUTOIMMUNE DISEASE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; B LYMPHOCYTE DIFFERENTIATION; BEHCET DISEASE; CLINICAL TRIAL; COUGHING; DERMATOMYOSITIS; DISEASE ACTIVITY; DOSE RESPONSE; DRUG ERUPTION; DRUG MECHANISM; DRUG RESPONSE; DRUG TOLERABILITY; HUMAN; IMMUNOPATHOLOGY; INFLAMMATORY DISEASE; LYMPHOCYTE DEPLETION; NONHODGKIN LYMPHOMA; NONHUMAN; PATHOPHYSIOLOGY; PRURITUS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; VASCULITIS; WEGENER GRANULOMATOSIS; BIOLOGICAL MODEL; CLINICAL PRACTICE; IMMUNOLOGY; LEUKAPHERESIS; METHODOLOGY; TREATMENT OUTCOME;

B-LYMPHOCYTES; CLINICAL TRIALS; HUMANS; LEUKOCYTE REDUCTION PROCEDURES; MODELS, IMMUNOLOGICAL; PHYSICIAN'S PRACTICE PATTERNS; RHEUMATIC DISEASES; TREATMENT OUTCOME;

EID: 25144497000     PISSN: None     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Protheroe A, Edwards JC, Simmons A, Maclennan K, Selby P. Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma. Rheumatology (Oxford). 1999;38:1150-1152.
2. Schroder AE, Greiner A, Seyfert C, Berek C. Differentiation of B cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis. Proc Natl Acad Sci U S A. 1996;93:221-225.
3. Pistoia V, Corcione A. Relationships between B cell cytokine production in secondary lymphoid follicles and apoptosis of germinal center B lymphocytes. Stem Cells. 1995;13:487-500.
4. Zhang Z, Bridges SL Jr. Pathogenesis of rheumatoid arthritis: role of B lymphocytes. Rheum Dis Clin North Am. 2001;27:335-353.
5. Edwards JCW, Cambridge G, Abrahams VM. Do self-perpetuating lymphocytes drive human autoimmune disease? Immunology. 1999;97:188-196.
6. Randen I, Brown D, Thompson KM, et al. Clonally related IgM rheumatoid factors undergo affinity maturation in the rheumatoid synovial tissue. J Immunol. 1992;148:3296-3301.
7. Schellekens GA, de Jong BAW, van den Hoogen FHJ, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognised by rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1998;101:273-281.
8. Roosnek E, Lanzavecchia A. Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells. J Exp Med. 1991;173:487-489.
9. Edwards JCW, Cambridge G. Rheumatoid arthritis: the predictable effect of small immune complexes in which antibody is also antigen. Br J Rheumatol. 1998;37:126-130.
10. Matsumoto I, Staub A, Benoist C, Mathis D. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science. 1999;286:1732-1735.
11. Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM. T cell activation in rheumatoid synovium is B cell dependent. J Immunol. 2001;167:4710-4718.
12. Dorner T, Farner NL, Lipsky PE. Ig lambda and heavy chain gene usage in early untreated systemic lupus erythematosus suggests intensive B cell stimulation. J Immunol. 1999;163:1027-1036.
13. Lipsky PE. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol. 2001;2:764-766.
14. Odendahl M, Jacobi A, Hansen A, et al. Disturbed peripheral B lymphocytes in systemic lupus erythematosus. J Immunol. 2000;165:5970-5979.
15. Chan OT, Hannum LG, Haberman AM, Madaio MP, Shlomchik MJ. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med. 1999;189:1639-1648.
16. Chan OTM, Madaio MP, Schlomchik MJ. The central and multiple roles of B cells in lupus pathogenesis. Immunol Rev. 1999;169:107-121.
17. Chan OTM, Madaio MP, Schlomchik MJ. B cells are required for lupus nephritis in the polygenic, Fas-intact MRL model of systemic autoimmunity. J Immunol. 1999;163:3592-3596.
18. Khare SD, Sarosi I, Xia XZ, et al. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci U S A. 2000;97:3370-3375.
19. Mackay F, Woodcock SA, Lawton P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med. 1999;190:1697-1710.
20. Gross JA, Johnston J, Mudri S, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000;404:995-999.
21. Ishikawa S, Sato T, Abe M, et al. Aberrant high expression of B lymphocyte chemokine (BLC/CXCL13) by C11b+CD11c+ dendritic cells in murine lupus and preferential chemotaxis of B1 cells towards BLC. J Exp Med. 2001;193:1393-1402.
22. Petri M, Stohl W, Chatham W, et al. BLyS plasma concentrations correlate with disease activity and levels of anti-dsDNA autoantibodies and immunoglobulins (Ig) in a SLE patient observational study [abstract]. Arthritis Rheum. 2003;48(suppl9):S655.
23. Collins CE, Gavin AL, Nemazee D, Stohl W. BLyS isoform expression in patients with SLE [abstract]. Arthritis Rheum. 2004;50 (suppl9):S461.
24. Petri M, Stohl W, Chatham W, et al. Association of BLyS with measures of disease activity in a prospective SLE observational study [abstract]. Arthritis Rheum. 2004;50(suppl9):S603.
25. Bohnhorst JO, Thoen JE, Natvig JB, Thompson KM. Significantly depressed percentage of CD27+ (memory) B cells among peripheral blood cells in patients with primary Sjogren's syndrome. Scand J Immunol. 2001;54:421-427.
26. Bohnhorst JO, Bjorgan MB, Thoen JE, Natvig JB, Thompson KM. Bm1-Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjogren's syndrome. J Immunol. 2001;167:3610-3618.
27. Hansen A, Odendahl M, Reiter K, et al. Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjogren's syndrome. Arthritis Rheum. 2002;46:2160-2171.
28. Adamson TC III, Fox RI, Frisman DM, Howell FV. Immunohistologic analysis of lymphoid infiltrates in primary Sjogren's syndrome using monoclonal antibodies. J Immunol. 1983;130:203-208.
29. Popa ER, Stegman CA, Bos NA, Kallenberg CG, Tervaert JW. Differential B- and T-cell activation in Wegener's granulomatosis. J Allergy Clin Immunol. 1999;103:885-894.
30. Heeringa P, Tervaert JW. Pathophysiology of ANCA-associated vasculitides: are ANCA really pathogenic? Kidney Int. 2004;65:1564-1567.
31. Huugen D, Tervaert JW, Heeringa P. Antineutrophil cytoplasmic autoantibodies and pathophysiology: new insights from animal models. Curr Opin Rheumatol. 2004;16:4-8.
32. Weidner S, Neupert W, Goppelt-Struebe M, Rupprecht HD. Antineutrophil cytoplasmic antibodies induce human monocytes to produce oxygen radicals in vitro. Arthritis Rheum. 2001;44:1698-1706.
33. Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest. 2002;110:955-963.
34. Engel AG, Arahata K. Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases and implications for the pathogenesis of the different myopathies. Hum Pathol. 1986;17:704-721.
35. Miller FW, Love LA, Barbieri SA, Balow JE, Plotz PH. Lymphocyte activation markers in idiopathic myositis: changes with disease activity and differences among clinical and autoantibody subgroups. Clin Exp Immunol. 1990;81:373-379.
36. Pachman LM. An update on juvenile dermatomyositis. Curr Opin Rheumatol. 1995;7:437-441.
37. O'Gorman MR, Corrochano V, Roleck J, Donovan M, Pachman LM. Flow cytometric analyses of the lymphocyte subsets in peripheral blood of children with untreated juvenile dermatomyositis. Clin Diagn Lab Immunol. 1995;3:205-208.
38. Hamzaoui K, Kahan A, Hamza M, Ayed K. Suppressive T cell function of Epstein-Barr virus induced B cell activation in active Behcet's disease. Clin Exp Rheumatol. 1991;9:131-135.
39. Eksioglu-Demiralp E, Kibaroglu A, Direskeneli H, et al. Phenotypic characteristics of B cells in Behcet's disease: increased activity in B cell subsets. J Rheumatol. 1999;26:826-832.
40. Suh CH, Park YB, Song J, Lee CH, Lee SK. Oligoclonal B lymphocyte expansion in the synovium of a patient with Behcet's disease. Arthritis Rheum. 2001;44:1707-1712.
41. Furie R, Stohl W, Ginzler E, et al. Safety, pharmacokinetic and pharmacodynamic results of a phase 1 single and double dose-escalation study of LymphoStat-B (human monoclonal antibody to BLyS) in SLE patients [abstract]. Arthritis Rheum. 2003;48 (suppl9):S377.
42. Wendy B, Halpern G, Lappin P, et al. Effects of LymphoStat-B, a BLyS antagonist, when administered intravenously to cynomolgus monkeys [abstract]. Arthritis Rheum. 2003;48(suppl9):S594.
43. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human antibody to CD20. Blood. 1994;83:435-445.
44. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833.
45. Johnson P, Glennie M. The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol. 2003;30(suppl2):3-8.
46. Edwards JCW, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford). 2001;40:205-211.
47. De Vita S, Zaja F, Sacco S, De Candia A, Fanin R, Ferraccioli G. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis. Arthritis Rheum. 2002;46:2029-2033.
48. Kramm H, Hansen KE, Gowing E, Bridges A. Successful therapy of rheumatoid arthritis with rituximab. Renewed interest in the role of B cells in the pathogenesis of rheumatoid arthritis. J Clin Rheumatol. 2004;10:28-32.
49. Kneitz C, Wilhelm M, Tony HP. Improvement of refractory rheumatoid arthritis after depletion of B cells. Scand J Rheumatol. 2004;33:82-86.
50. Leandro MJ, Edwards JCW, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis. 2002;61:883-888.
51. Cambridge G, Leandro MJ, Edwards JC, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 2003;48:2146-2154.
52. Edwards JCW, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350:2572-2581.
53. Anolik JH, Campbell D, Felgar R, Rosenblatt J, Young F, Looney RJ. Phase I/II trial of rituximab in SLE [abstract]. Arthritis Rheum. 2002;46(suppl9):S289.
54. Looney RJ, Anolik J, Sanz I. B cells as therapeutic targets for rheumatic diseases. Curr Opin Rheumatol. 2004;16:180-185.
55. Anolik JH, Campbell D, Felgar RE, et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 2003;48:455-459.
56. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99:754-758.
57. Anolik JH, Barnard J, Cappione AJ III, Felgar RE, Looney RJ, Sanz I. Rituximab has a positive impact on B cell tolerance defects in human SLE [abstract]. Arthritis Rheum. 2004;50(suppl9):S646.
58. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002;46:2673-2677.
59. Leandro MJ, Edwards JCW, Ehrenstein MR, Cambridge G, Isenberg DA. B lymphocyte depletion in the treatment of systemic lupus erythematosus [abstract]. Arthritis Rheum. 2004;50(suppl9):S447.
60. Albert DA, Khan SR, Stansberry J, Tsai D, Eisenberg RA. A phase I trial of rituximab (anti-CD20) for treatment of systemic lupus erythematosus [abstract]. Program and abstracts of the 67th Annual Scientific Meeting of the American College of Rheumatology; October 23-28, 2003; Orlando, Florida. Abstract LB9. Available at: http://www.rheumatology.org/annual/abstracts/index.asp Accessed January 10, 2005.
61. Albert D, Khan S, Stansberry J, et al. A phase I trial of rituximab (anti-CD20) for treatment of systemic lupus erythematosus [abstract]. Arthritis Rheum. 2004;50(suppl9):S446.
62. Kneitz C, Wilhelm M, Tony HP. Effective B cell depletion with rituximab in the treatment of autoimmune diseases. Immunobiology. 2002;206:519-527.
63. Petschner F, Walker UA, Schmitt-Graff A, Uhl M, Peter HH. "Catastrophic systemic lupus erythematosus" with Rosai-Dorfman sinus histiocytosis. Successful treatment with anti-CD/rituximab. Dtsch Med Wochenschr. 2001;126:998-1001.
64. Fra GP, Avanzi GC, Bartoli E. Remission of refractory lupus nephritis with a protocol including rituximab. Lupus. 2003:12:783-787.
65. Weide R, Heymanns J, Pandorf A, Koppler H. Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy. Lupus. 2003;12:779-782.
66. Specks U, Fervenza FC, McDonald TJ, Hogan MC. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum. 2001;44:2836-2840.
67. Levine TD. A pilot study of rituximab therapy for refractory dermatomyositis [abstract]. Arthritis Rheum. 2002;46(suppl9):S488.
68. Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52:262-268.